The companion animal pharmaceuticals market size was valued at USD 16.98 billion in 2025 and is projected to grow from USD 18.03 billion in 2026 to USD 29.47 billion by 2034, registering a CAGR of 6.34% during the forecast period (2026–2034). North America dominated the companion animal pharmaceuticals market with a market share of 40.71% in 2025.
Companion animal pharmaceuticals include medicines, vaccines, parasiticides, anti-infectives, pain management drugs, and specialty therapeutics to prevent and treat diseases in pets such as dogs, cats, horses, and other companion animals. These products support animal health, improve quality of life, and enhance disease management through preventive and therapeutic care. They are widely used in veterinary hospitals, clinics, animal shelters, and home healthcare settings for chronic disease management and emergency treatment.
The companion animal pharmaceuticals market demand is increasing due to rising pet ownership, growing spending on animal healthcare, and increasing awareness of preventive veterinary care. Continuous product innovation, expanding veterinary services, and advancements in biologics and targeted therapies are further supporting companion animal pharmaceuticals market growth.
Download a Free Sample to Explore Detailed Market Insights
The companion animal pharmaceuticals market has indirect exposure to supply chain disruptions due to its dependence on active pharmaceutical ingredients, biologics, packaging materials, cold chain logistics, and global manufacturing networks. Disruptions in raw material sourcing, transportation, and production schedules can delay product availability, increase manufacturing costs, and create temporary shortages of essential veterinary medicines and vaccines across multiple regions. These challenges encourage manufacturers to diversify suppliers, strengthen regional production capabilities, optimize inventory management, and invest in resilient distribution networks to ensure consistent product availability worldwide. The market is demonstrating a capacity-constrained recovery, supported by expanding manufacturing capacity, improved supply chain resilience, strategic sourcing initiatives, and increasing investments in localized production and logistics infrastructure.
The companion animal pharmaceuticals market is witnessing a transition from treatment-focused veterinary care to preventive healthcare and routine wellness programs. Pet owners are increasingly prioritizing vaccinations, parasite prevention, nutritional supplements, and regular health screenings to improve long-term animal health and reduce disease risks. This shift is driving consistent demand for preventive pharmaceuticals and expanding recurring veterinary visits. For example, Zoetis continues to expand its portfolio of vaccines and parasiticides that support preventive care for dogs, cats, and horses.
The companion animal pharmaceuticals market is experiencing a shift toward advanced biologics, particularly monoclonal antibody therapies, for managing chronic diseases in companion animals. Veterinary professionals are increasingly prescribing these targeted treatments for conditions such as osteoarthritis pain and atopic dermatitis because they offer efficacy with fewer systemic side effects than many conventional drugs. This transition is accelerating innovation in specialty veterinary medicine and expanding the biologics segment of the market.
The companion animal pharmaceuticals market forecasts continued investment activity driven by rising pet healthcare expenditure, demand for innovative therapeutics, and growing adoption of precision veterinary medicine. Investors are prioritizing companies developing monoclonal antibodies, vaccines, parasiticides, and digital veterinary health solutions that improve treatment outcomes and strengthen animal healthcare capabilities.
Key Investment and Funding Activities in Companion Animal Pharmaceuticals Market, 2025–2026
Elanco Animal Health
USD 25 million
In June 2026, Elanco launched Elanco Ventures to invest in animal health therapeutics, emerging technologies, and One Health innovations, including companion animal healthcare solutions.
USD 400 million
In December 2025, Elanco invested to expand its US manufacturing footprint, strengthen R&D capabilities, and increase monoclonal antibody manufacturing capacity supporting next generation companion animal therapeutics.
Growing Pet Humanization and Expanding Availability of Species-specific Pharmaceuticals Drives Market
The rising population of companion animals and growing humanization of pets are increasing demand for veterinary pharmaceuticals, as owners invest more in preventive care and advanced treatments. This trend is accelerating the use of vaccines, parasiticides, and chronic disease therapies while expanding pharmaceutical demand globally.
The growing availability of species specific pharmaceuticals is driving demand in the companion animal pharmaceuticals market by improving treatment efficacy and safety for dogs, cats, and horses. Veterinary medicine is shifting away from the off-label use of human drugs toward therapies specifically developed for companion animals, resulting in better clinical outcomes and owner compliance. This trend is encouraging greater investment in veterinary drug development and regulatory approvals. The increasing approval and adoption of species-specific monoclonal antibodies, long acting parasiticides, and feline only analgesics are expanding treatment options for previously underserved conditions in companion animals.
Rising Antimicrobial Stewardship and High Cost of Advanced Companion Animal Pharmaceuticals Restrain Market Expansion
Increasing antimicrobial stewardship initiatives and tighter regulations on veterinary antibiotic use are limiting the routine prescription of companion animal anti-infectives. Veterinary professionals are encouraged to reserve critically important antibiotics for confirmed bacterial infections, reducing demand for several conventional pharmaceutical products. While these measures help combat antimicrobial resistance, they also constrain sales growth within the veterinary anti-infective segment.
High cost of products increases the financial burden on pet owners for long term treatment of chronic diseases and specialty biologics. For example, Zoetis offers monoclonal antibody therapies such as Librela for canine osteoarthritis, which require repeated monthly Administration and are priced significantly higher than conventional NSAIDs. The recurring treatment expense discourages many pet owners from continuing long-term therapy, particularly in emerging and price sensitive markets, thereby restraining broader adoption of advanced companion animal pharmaceuticals.
Expansion of Veterinary Telehealth and Increasing Demand for Age-related Chronic Diseases Offer Growth Opportunities to Market Players
The rapid adoption of veterinary telehealth and digital pharmacy platforms is expanding access to prescription medications beyond traditional clinic visits. This creates new revenue opportunities for pharmaceutical manufacturers and online veterinary pharmacy providers by improving treatment adherence and repeat prescription sales. Companies such as Chewy and Covetrus are strengthening digital pharmacy ecosystems to support remote prescribing. As virtual veterinary consultations become more widely accepted, digital pharmaceutical distribution is expected to become a major growth channel.
The increasing lifespan of companion animals is leading to a higher prevalence of age related disorders, including osteoarthritis, chronic kidney disease, cognitive dysfunction, endocrine disorders, and cardiovascular conditions that require continuous pharmacological management. This creates substantial opportunities for pharmaceutical manufacturers to develop innovative long-term therapies with improved safety, efficacy, and ease of administration.
Increasing Shortage of Veterinary Professionals and Consolidation of Veterinary Clinics Intensifies Pricing Pressure Challenges Market Growth
The global shortage of veterinarians and veterinary technicians is reducing the capacity of clinics to diagnose diseases, monitor chronic conditions, and prescribe advanced pharmaceutical therapies. Longer appointment wait times and limited specialist availability delay treatment initiation and reduce prescription volumes, particularly for complex diseases requiring continuous monitoring. This limits the commercial potential of innovative companion animal pharmaceuticals despite growing demand. For example, the American Veterinary Medical Association continues to report workforce shortages across companion animal practices in the US, contributing to reduced access to veterinary care in several regions.
The growing consolidation of veterinary practices into large corporate hospital networks is strengthening the bargaining power of buyers. These organizations negotiate centralized procurement contracts, demand volume-based discounts, and increasingly favor standardized formularies. As a result, pharmaceutical manufacturers face pricing pressure, reduced product differentiation, and greater difficulty securing formulary inclusion, limiting revenue growth despite rising companion animal healthcare expenditure.
The parasiticides & ectoparasiticides segment accounted for a share of 29.35% in 2025, owing to flea, tick, and mite prevention in companion animals and routine veterinarian recommendations for parasite control. Regular repeat dosing and broad use across different pet age groups continue to support strong prescription and retail sales.
The anti-inflammatory & analgesics segment is expected to grow at a CAGR of around 6.91% during the forecast period due to increasing treatment of osteoarthritis and post-surgical pain in aging pets. Greater availability of long-acting pain therapies and improved veterinary pain management protocols are further supporting segment growth.
In 2025, dogs accounted for a share of 59.47% due to higher veterinary visit frequency, greater demand for preventive medicines, and wider use of chronic disease treatments. Dogs also receive more routine vaccinations, parasite control products, and prescription therapies than other companion animals.
The cats segment is expected to grow at a CAGR of 7.04% during the forecast period, driven by increasing cat ownership and rising demand for feline specific medicines with easier administration. Improved diagnosis of chronic kidney disease, thyroid disorders, and arthritis is also supporting pharmaceutical use.
The infectious diseases segment accounted for a share of 29.63% in 2025 due to frequent treatment of bacterial, viral, and parasitic infections in companion animals and continued vaccination support. High clinical demand for anti-infectives and rapid disease management sustains consistent pharmaceutical consumption.
The dermatologic diseases segment is expected to grow at a CAGR of 7.18% during the forecast period, driven by increasing cases of allergic dermatitis and skin infections linked to environmental allergens and parasites. Growing use of targeted therapies and long-term treatment plans is supporting sustained demand.
The veterinary hospitals & clinics segment accounted for a share of 52.80% in 2025, as prescription medicines are primarily dispensed after veterinary examination and diagnosis. Access to professional treatment, vaccination services, and follow-up care keeps pharmaceutical purchasing concentrated through these facilities.
The online/e-commerce segment is projected to grow at a CAGR of 7.22% during the forecast timeframe, as pet owners increasingly purchase refill medications and preventive products through digital platforms. Home delivery, subscription services, and wider product availability are improving purchasing convenience and repeat orders.
North America: Market Dominance Led by High Pet Healthcare Spending and Strong Veterinary Care Infrastructure
The North America companion animal pharmaceuticals market accounted for the largest regional share of 40.71% in 2025, driven by high expenditure on companion animal healthcare, well-established veterinary service networks, and broad insurance coverage for pets. Strong compliance with preventive treatment schedules and early disease diagnosis also sustain pharmaceutical demand.
The US companion animal pharmaceuticals market was valued at USD 6.01 billion in 2025, driven by widespread pet insurance adoption, high prescription medicine utilization, and rapid uptake of newly approved veterinary therapeutics. Digital pharmacy access and routine preventive care further support medicine demand across companion animals. According to the North American Pet Health Insurance Association (NAPHIA), 7.03 million pets were insured in the US at the end of 2025, indicating expanding access to veterinary treatments.
The companion animal pharmaceuticals market in Canada was valued at USD 898.76 million in 2025, supported by increasing demand for feline specific therapeutics, greater use of preventive parasite control across all seasons, and rising veterinary management of chronic age-related conditions in companion animals. Expanding access to veterinary pharmacies, higher acceptance of prescription medicines for long term treatment, and growing preference for licensed veterinary products over-the-counter alternatives continue to strengthen pharmaceutical demand across the country.
Asia Pacific: Fastest Growth Driven by Expanding Veterinary Access and Rising Demand for Companion Animal Therapeutics
The Asia Pacific companion animal pharmaceuticals market is expected to grow at a CAGR of 8.26% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding companion animal veterinary networks, increasing availability of locally manufactured veterinary pharmaceuticals, and growing adoption of preventive vaccination and parasite-control programs. Rising demand for prescription medicines for chronic and lifestyle-related pet conditions, along with improving access to specialized veterinary care across developing economies, continues to accelerate market growth.
The China companion animal pharmaceuticals market was valued at USD 944.26 million in 2025, supported by expansion of licensed companion animal hospitals, increasing domestic production of veterinary pharmaceuticals, and rising demand for prescription medicines for urban pet populations. Greater availability of advanced diagnostics, stronger veterinary prescribing practices, and growing use of disease-specific therapies for companion animals continue to support sustained pharmaceutical market growth across the country.
The India companion animal pharmaceuticals market was valued at USD 482.98 million in 2025, fueled by expansion of NABH accredited veterinary hospitals, rising availability of indigenous veterinary pharmaceutical formulations, and increasing demand for companion animal vaccination through organized veterinary networks. The growing presence of veterinary colleges and referral pet hospitals is strengthening access to specialized treatment. According to the Veterinary Council of India, India has more than 70 veterinary colleges, supporting the country's expanding companion animal healthcare ecosystem.
The Japan companion animal pharmaceuticals market was valued at USD 557.26 million in 2025, supported by Increasing demand for medicines targeting age related companion animal disorders, widespread use of regular health screening for pets, and high adoption of premium prescription therapies. Strong preference for long-term disease management, precise dosing formulations, and specialized veterinary care continues to support stable pharmaceutical demand throughout the country.
The companion animal pharmaceuticals market competitive landscape is moderately fragmented, with competition driven by global animal health companies and regional veterinary pharmaceutical manufacturers. Leading players compete through broad product portfolios, strong veterinary partnerships, continuous product innovation, and regulatory compliance. Emerging companies focus on niche therapeutics, affordable formulations, and expanding distribution across veterinary clinics and online channels. The Companion Animal Pharmaceuticals Market ecosystem is influenced by rising pet ownership, increasing focus on preventive healthcare, growing demand for specialized treatments, evolving veterinary practices, and wider access to companion animal healthcare products.
June 2026: Elanco Animal Health announced USDA approval for TruCan Ultra Lyme-L4, a combination vaccine for dogs that protects against Lyme disease and leptospirosis.
March 2026: Merck Animal Health received US FDA approval for an expanded BRAVECTO QUANTUM label, adding protection against Asian longhorned and Gulf Coast ticks for dogs.
September 2025: Virbac announced the European launch of Vikaly, the world's first medicated feed for cats.
September 2025: Elanco Animal Health announced that the US FDA approved an updated label for Zenrelia, removing previous vaccine-induced disease language following review of additional clinical data.
September 2025: Merck Animal Health announced that Health Canada approved BRAVECTO QUANTUM, a once-yearly injectable flea and tick treatment for dogs.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com